Last reviewed · How we verify

Eylea® (Aflibercept)

Alvotech Swiss AG · Phase 3 active Small molecule

Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.

Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye. Used for Wet age-related macular degeneration (wAMD), Diabetic macular edema (DME), Macular edema following retinal vein occlusion (RVO).

At a glance

Generic nameEylea® (Aflibercept)
SponsorAlvotech Swiss AG
Drug classVEGF inhibitor / Soluble decoy receptor
TargetVEGF-A, VEGF-B, PlGF (Placental Growth Factor)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their endogenous receptors on endothelial cells, thereby reducing pathological neovascularization and vascular permeability in retinal diseases. This mechanism is particularly effective in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results